Standard Biotools INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Standard BioTools Inc. reported a widened net loss in Q3 2025, driven by restructuring charges and a decline in revenue, while progressing with the divestiture of its SomaScan Business.
NASDAQ
Standard BioTools Inc. reported a reduced net loss in Q2 2025, driven by lower operating expenses and the strategic divestiture of its SomaScan business to Illumina for up to $425 million.
NASDAQ
Standard BioTools' Q1 2025 revenue decreased by 10% year-over-year, reflecting ongoing integration efforts and shifts in sales mix.
NASDAQ
Standard BioTools' Q3 2024 results reflect a significant increase in revenue and a net loss, heavily influenced by the recent merger with SomaLogic.
NASDAQ
Standard BioTools' Q2 2024 results reflect the impact of the SomaLogic merger, including increased revenue and operating expenses, alongside restructuring efforts.
NASDAQ
Standard BioTools' first quarter of 2024 saw a significant revenue increase of 81% year-over-year, primarily driven by the acquisition of SomaLogic.